Disease Team Sign off Process

The Protocol Review and Monitoring Committee reviews all cancer related protocols in start-up. The purpose of the **Disease Team Sign Off** process is to identify potential collaboration between the consortium partners. The DTSo process needs to be completed prior to submitting the PRMC Application.

The steps to complete the DTSo process are as follows: **IITs skip to #3 / Coop Studies skip to #4**

1. Each study team must make the Sponsor aware of Case Comprehensive Cancer Center’s consortium structure. More information is available on the Case CCC website: [https://case.edu/cancer/about-us/consortium-institutions](https://case.edu/cancer/about-us/consortium-institutions)

2. When making the Sponsor aware of the consortium structure, confirm if the study can be opened at the other institution.

3. **If the study can be opened at the other institution,** email that institution’s respective Disease Team Leader. CC your home site Disease Team Leader and PI. (Email template on page 2)

4. **If the study cannot be opened at the other institution,** send a notification email to the other institution’s respective Disease Team Leader. (Email templates on page 2/3)

5. Save the email responses from the Sponsor and Disease Team Leader to upload in the PRMC application.
DTSO Email Templates

If the study **can** be opened at the other institution:

**Subject:** PRMC Disease Team Sign Off: (Study #) – Response Needed  
**To:** Consortium Partner’s Disease Team Leader and RC  
**CC:** Home Site Disease Team Leader and PI

Hello Dr. XXX,

The attached protocol is in start-up at (CC/UH). Please review and confirm if you are interested in opening this study in your disease group.

Thank you,

If the study **cannot** be opened at the other institution:

**Subject:** PRMC Disease Team Sign Off Notification: (Study #)  
**To:** Consortium Partner’s Disease Team Leader and RC

Hello Dr. XXX,

The attached protocol is in start-up at (CC/UH). Per the Sponsor, (reasoning why the study cannot be opened at the other site – Example: “Per the Sponsor, UH may not participate as there are a limited number of sites they have approved to open the study. Sponsor is willing to consider another site in the future if further cohorts open or other sites are unable to meet enrollment goals.”)

Thank you,
DTSO Email Templates

Coop Studies:

**Subject:** PRMC Disease Team Sign Off Notification: (Study #)  
**To:** Consortium Partner’s Disease Team Leader and RC

Hello Dr. XXX,

The attached protocol is in start-up at (CC/UH).

Thank you,
CASE CCC DISEASE TEAM LEADERS

**Breast – ID # 1**
UH: Alberto Montero, MD - alberto.montero@uhhospitals.org
UH: Nicole McClain - nicole.mcclain@uhhospitals.org
CC: Halle Moore, MD - moorehl1@ccf.org
CC: Katie Gardner - GARDNEK5@ccf.org

**Gastrointestinal – ID # 2**
UH: Anit Mahipal, MD - amit.mahipal@uhhospitals.org
UH: Rachel Carney - Rachel.carney@uhhospitals.org
CC: Smitha Krishnamurthi, MD - krishns3@ccf.org
CC: Natalia Rosas - rosasn@ccf.org

**Brain – ID #3**
UH: Herbert Newton, MD - Herbert.Newton@UHhospitals.org
UH: Joyce Callahan - joyce.callahan@uhhospitals.org
CC: Gene Barnett, MD - barnetg@ccf.org
CC: Theresa Naska - naskat@ccf.org

**Head & Neck – ID #3**
UH: Rod Rezaee, MD - rod.rezaee@uhhospitals.org
UH: Joyce Callahan - joyce.callahan@uhhospitals.org
CC: Jessica Geiger, MD - geigerj@ccf.org
CC: Jennie Laeng - LAENGJ@ccf.org

**Thoracic – ID #5**
UH: Debora Bruno, MD - Debora.Bruno@UHhospitals.org
UH: Carol Tackett - carol.tackett@uhhospitals.org
CC: Nathan Pennell MD, PhD - penneln@ccf.org
CC: Jennie Laeng - LAENGJ@ccf.org

**Melanoma – ID #6**
UH: Jeremy Bordeaux, MD - Jeremy.Bordeaux@UHhospitals.org
UH: Carol Tackett - carol.tackett@uhhospitals.org
CC: James Isaacs, MD - isaacsj3@ccf.org
CC: Natalia Rosas - rosasn@ccf.org

**Sarcoma – ID #7**
UH: Ankit Mangla, MD - ankit.mangla@uhhospitals.org
UH: Carol Tackett - carol.tackett@uhhospitals.org
CC: Dale Shepard, MD, PhD - shepard@ccf.org
CC: Sarah Abdelwahab - abdelws@ccf.org
**CASE CCC DISEASE TEAM LEADERS**

**Pediatric**
UH: John Letterio, MD - john.letterio@uhhospitals.org  
UH: Kristin Leuchtag - Kristin.leuchtag@uhhospitals.org  
CC: Rabi Hanna, MD - hannar2@ccf.org  
CC: Tina Ours - ourst@ccf.org

**Genitourinary – ID #8**
UH: Pedro Barata, MD - pedro.barata@uhhospitals.org  
UH: Rachel Carney - Rachel.carney@uhhospitals.org  
CC: Shilpa Gupta, MD - Guptas5@ccf.org  
CC: Katie Gardner - GARDNEK5@ccf.org

**Gynecologic – ID #8**
UH: Sarah Lynam, MD - Sarah.Lynam@UHhospitals.org  
UH: Leslie Ortega - Leslie.Ortega@UHhospitals.org  
CC: Robert Debernardo, MD - debernr@ccf.org  
CC: Megan Park – parkm2@ccf.org

**Leukemia – ID #9**
UH: Ben Tomlinson, MD - Benjamin.Tomlinson@UHhospitals.org  
UH: Leslie Ortega - leslie.ortega@uhhospitals.org  
CC: Hetty Carraway, MD - carrawh@ccf.org  
CC: Natalia Rosas - rosasn@ccf.org

**Lymphoma – ID #4**
UH: Chanchung (George) Deng, MD - Changchun.Deng@UHhospitals.org  
UH: Leslie Ortega - leslie.ortega@uhhospitals.org  
CC: Brian Hill, MD - hillb2@ccf.org  
CC: Katie Gardner - GARDNEK5@ccf.org

**Multiple Myeloma – ID # A**
UH: Koen van Besien, MD - Koen.vanBesien@UHhospitals.org  
UH: Leslie Ortega - leslie.ortega@uhhospitals.org  
CC: Jason Valent, MD - valentj3@ccf.org  
CC: Jennie Laeng - LAENGJ@ccf.org

**BMT**
UH: Koen van Besien - Koen.vanBesien@UHhospitals.org  
UH (IIT): Barb Calabro - barbara.calabro@uhhospitals.org  
UH: Joyce Callahan - joyce.callahan@uhhospitals.org  
CC: Craig Sauter, MD - sautercc@ccf.org  
CC: Sarah Abdelwahab - abdelws@ccf.org
CASE CCC DISEASE TEAM LEADERS

Phase I – ID #Y
UH: Afshin Dowlati, MD - afshin.dowlati@uhhospitals.org
UH: Kim Thomas - Kimberly.Thomas@UHhospitals.org
CC: Dale Shepard, MD, PhD - shepard@ccf.org
CC: Sarah Abdelwahab - abdelws@ccf.org

Radiation Oncology
UH: Specific disease team leader
CC: Chirag Shah, MD - shahc4@ccf.org
CC: Jennie Laeng - LAENGJ@ccf.org